ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections
Purpose of this study is to evaluate the safety, tolerability, antiviral activity, and pharmacokinetic behavior of ISIS 14803 administered for up to 12 weeks by intravenous infusions in patients with chronic hepatitis C.
|Study Design:||Primary Purpose: Treatment|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00035945
|United States, California|
|Carlsbad, California, United States, 92008|